The stomach as an energy homeostasis regulating center. An approach for obesity

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 4, Issue 1, 2010, Pages 75-84

  Al Massadi, Omar ^a,b   Pardo, María ^a,b   Casanueva, Felipe F ^a,b,c   Seoane, Luisa M ^a,b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

CCK; Ghrelin; GLP 1; Myenteric plexus; PYY (3 36); Stomach; Tease feeding

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ANTIOBESITY AGENT; CHOLECYSTOKININ; ENDOCANNABINOID; GHRELIN; GLUCAGON LIKE PEPTIDE 1; OBESTATIN; PEPTIDE YY; PEPTIDE YY [3-36]; RIMONABANT;

ANXIETY; DEPRESSION; DIARRHEA; DIGESTIVE FUNCTION; DRUG MECHANISM; ENERGY BALANCE; GASTROINTESTINAL TRACT; HOMEOSTASIS AND REGULATION; HORMONAL REGULATION; HUMAN; IRRITABILITY; NAUSEA; NERVOUS SYSTEM; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STOMACH; UNSPECIFIED SIDE EFFECT;

EID: 77951143117     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221410790226729     Document Type: Review

References (76)

1. Frühbeck G. Are we really tackling the obesityepidemic? Obesity Metab 2008; 4 (2): 91-95.
2. Scopinaro N, Papadia F, Camerini G, Marinari G, Civalleri D, Gian FA. A comparison of a personal series of biliopancreatic diversion and literature data on gastric bypass help to explain the mechanisms of resolution of type 2 diabetes by the two operations. Obes Surg 2008; 18: 1035-1038.
3. Buchwald H, Estok R, Fahrbach K, Banel D, Sledge I. Trends in mortality in bariatric surgery: A systematic review and metaanalysis. Surgery 2007; 142: 621-632.
4. Tice JA, Karliner L, Walsh J, Petersen AJ, Feldman MD. Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures. Am J Med 2008; 121: 885-893.
5. Konturek SJ, Brzozowski T, Konturek PC, et al. Brain-gut and appetite regulating hormones in the control of gastric secretion and mucosal protection Review. J Physiol Pharmacol 2008; 59 (Suppl 2): 7-31.
6. Grundy D. Signalling the state of the digestive tract. Auton Neurosci 2006; 125: 76-80.
7. Sawchenko PE. Central connections of the sensory and motor nuclei of the vagus nerve. J Auton Nerv Syst 1983; 9(1): 13-26.
8. Berthoud HR. The vagus nerve, food intake and obesity. Regul Pept 2008; 149: 15-25.
9. Solomon A, De Fanti BA, Martinez JA. The nucleus tractus solitari (NTS) participates in peripheral ghrelin glucostatic hunger signalling mediated by insulin. Neuropeptides 2006; 40: 169-175.
10. Seoane LM, Al-Massadi O, Caminos JE, Tovar SA, Dieguez C, Casanueva FF. Sensory stimuli directly acting at the central nervous system regulate gastric ghrelin secretion. An ex vivo organ culture study. Endocrinology 2007; 148(8): 3998-4006.
11. Burdyga G, Lal S, Varro A, Dimaline R, Thompson DG, Dockray GJ. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 2004; 24(11): 2708-2715.
12. Rehfeld JF. Accurate measurement of cholecystokinin in plasma. Clin Chem1998; 44: 991-1001.
13. Herrmann C, Göke R, Richter G, Fehmann HC, Arnold R, Göke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995; 56(2): 117-126.
14. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89(5): 1070-1077.
15. Inui A, Asakawa A, Bowers CY, et al. Ghrelin, appetite, and gastric motility: The emerging role of the stomach as an endocrine organ. FASEB J 2004; 18(3): 439-456.
16. Hellström PM. Faces of ghrelin-research for the 21st century. Neurogastroenterol Motil 2009; 21(1): 2-5.
17. Gibbs J, Young RC, Smith GP. Cholecystokinin elicits satiety in rats with open gastric fistulas. Nature 1973; 245(5424): 323-325.
18. Kissileff HR, Pi-Sunyer FX, Thornton J, Smith GP. C-terminal octapeptide of cholecystokinin decreases food intake in man. Am J Clin Nutr 1981; 34(2): 154-160.
19. Reubi JC, Waser B, Läderach U, et al. Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach. Gastroenterology 1997; 112(4): 1197-2005.
20. Smith GP, Jerome C, Cushin BJ, Eterno R, Simansky KJ. Abdominal vagotomy blocks the satiety effect of cholecystokinin in the rat. Science 1981; 213(4511): 1036-1037.
21. Moran TH, Baldessarini AR, Salorio CF, Lowery T, Schwartz GJ. Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin. Am J Physiol1997; 272(4 Pt 2): R1245-1251.
22. Kobelt P, Tebbe JJ, Tjandra I, et al. CCK inhibits the orexigenic effect of peripheral ghrelin. Am J Physiol Regul Integr Comp Physiol 2005; 288(3): R751-758.
23. Brubaker PL, Anini Y. Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Can J Physiol Pharmacol 2003; 81(11): 1005-1012.
24. Abbott CR, Monteiro M, Small CJ, et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagalbrainstem- hypothalamic pathway. Brain Res 2005; 1044(1): 127-131.
25. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3(3): 153-165.
26. Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 2005; 146(9): 3748-3756.
27. Näslund E, Bogefors J, Skogar S, et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 1999; 277(3 Pt 2): R910-916.
28. Gutzwiller JP, Drewe J, Goke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999; 276: R1541-R1544.
29. Conlon JM. The origin and evolution of peptide YY (PYY) and pancreatic polypeptide (PP). Peptides 2002; 23: 269-278.
30. Neary MT, Batterham RL. Gut hormones: Implications for the treatment of obesity. Pharmacol Ther 2009; 124: 44-56.
31. Wren AM. Gut and hormones and obesity. Front Horm Res 2008; 36: 165-181.
32. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349(10): 941-948.
33. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418: 650-654
34. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402(6762): 656-660.
35. Gutierrez JA, Solenberg PJ, Perkins DR, et al. Ghrelin octanoylation mediated by an orphan lipid transferase. Proc Natl Acad Sci USA 2008; 105(17): 6320-6325.
36. Yang J, Brown MS, Liang G, Grishin NV, Goldstein JL. Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 2008; 132(3): 387-396.
37. Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelinlike immunoreactivity levels in humans. J Clin Endocrinol Metab 2001; 86(10): 4753-4758.
38. Dornonville de la Cour C, Björkqvist M, Sandvik AK, et al. A-like cells in the rat stomach contain ghrelin and do not operate under gastrin control. Regul Pept 2001; 99(2-3): 141-150.
39. Cowley MA, Smith RG, Diano S, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 2003; 37(4): 649-661.
40. Barreiro ML, Gaytán F, Caminos JE, et al. Cellular location and hormonal regulation of ghrelin expression in rat testis. Biol Reprod 2002; 67(6): 1768-1776. (Pubitemid 35388007)
41. Caminos JE, Tena-Sempere M, Gaytán F, et al. Expression of ghrelin in the cyclic and pregnant rat ovary. Endocrinology 2003; 144(4): 1594-1602
42. Gaytan F, Barreiro ML, Chopin LK, et al. Immunolocalization of ghrelin and its functional receptor, the type 1a growth hormone secretagogue receptor, in the cyclic human ovary. J Clin Endocrinol Metab 2003; 88(2): 879-887.
43. Iglesias MJ, Piñeiro R, Blanco M, et al. Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes. Cardiovasc Res 2004; 62(3): 481-488.
44. Gualillo O, Caminos J, Blanco M, et al. Ghrelin, a novel placental-derived hormone. Endocrinology 2001; 142(2): 788-794.
45. Wren AM, Small CJ, Ward HL, et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000; 141(11): 4325-8328.
46. Tolle V, Bassant MH, Zizzari P, et al. Ultradian rhythmicity of ghrelin secretion in relation with GH, feeding behavior, and sleep-wake patterns in rats. Endocrinology 2002; 143(4): 1353-1361.
47. Murata M, Okimura Y, Iida K, et al. Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. J Biol Chem 2002; 277(7): 5667-5674.
48. Seoane LM, Al-Massadi O, Barreiro F, Dieguez C, Casanueva FF. Growth hormone and somatostatin directly inhibit gastric ghrelin secretion. An in vitro organ culture system. J Endocrinol Invest 2007; 30(9): 22-25.
49. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999; 20(3): 157-198.
50. Nagano M, Chastre E, Choquet A, Bara J, Gespach C, Kelly PA. Expression of prolactin and growth hormone receptor genes and their isoforms in the gastrointestinal tract. Am J Physiol 1995; 268(3 Pt 1): G431-442.
51. Di Vito L, Broglio F, Benso A, et al. The GH-releasing effect of ghrelin, a natural GH secretagogue, is only blunted by the infusion of exogenous somatostatin in humans. Clin Endocrinol (Oxf) 2002; 56(5): 643-648.
52. Shimada M, Date Y, Mondal MS, et al. Somatostatin suppresses ghrelin secretion from the rat stomach. Biochem Biophys Res Commun 2003; 302(3): 520-525.
53. Qi X, Reed J, Englander EW, Chandrashekar V, Bartke A, Greeley GH Jr. Evidence that growth hormone exerts a feedback effect on stomach ghrelin production and secretion. Exp Biol Med (Maywood). 2003; 228(9): 1028-1032.
54. Zhang JV, Ren PG, Avsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005; 310(5750): 996-999.
55. Goebel M, Stengel A, Taché Y. Continued controversy of obestatin as a gut hormone influencing food intake and gastrointestinal motility. Obesity Metab 2008; 4(3): 143-148.
56. Zhao CM, Furnes MW, Stenström B, Kulseng B, Chen D. Characterization of obestatin- and ghrelin-producing cells in the gastrointestinal tract and pancreas of rats: An immunohistochemical and electron-microscopic study. Cell Tissue Res 2008; 331(3): 575-587.
57. Seoane LM, Al-Massadi O, Pazos Y, Pagotto U, Casanueva FF. Central obestatin administration does not modify either spontaneous or ghrelin-induced food intake in rats. J Endocrinol Invest 2006; 29(8): RC13-15.
58. Zizarri P, Longchamps R, Epelbaum J, Bluet-Pajot MT. Obestatin partially affects ghrelin stimulation of food intake and GH secretion in rodents. Endocrinology 2007; 148(4): 1648-1653.
59. Hollister LE. Health aspects of cannabis. Pharmacol Rev 1986; 38: 1-20.
60. Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 2008; 51(8): 1356-1367.
61. Seoane LM, Lopez M, Tovar S, Casanueva FF, Senaris R, Dieguez C. Agouti-related peptide, neuropeptide Y, and somatostatin-producing neurons are targets for ghrelin actions in the rat hypothalamus. Endocrinology 2003; 144: 544-551
62. Thompson, R. J.: US20040107130A1 (2004).
63. Stack, R. S., Glenn, R. A., Athas, W. L., Williams, M. S., Moody, T.J., Silverstein, F. E., Every, N.: US20040117031A1 (2004).
64. Levine, A. H., Cvinar, J. F., Melanson, D., Meade, J.C.: WO2004049982A2 (2004).
65. Roth J., Baron, A., Parkes, D., Young, A., Anderson, C.M.: WO2007055743A2 (2007).
66. Pazos Y, Casanueva FF, Camiña JP. Basic aspects of ghrelin action. Vitam Horm 2008; 77: 89-119.
67. Perrissoud, D., Martinez, J., Moulin, Al.,Fehrentz, J.-A., Boeglin, D., Demange, L.: US20070037857A1 (2007).
68. Fraser, G.L., Hoveyda, H. R.,Peterson, M.L.: US20070021331A1(2007).
69. Hoveyda, H. R.,Peterson, M.L., Fraser, G. L., Ramaseshan, M.: US20060025566A1 (2006).
70. Zhang J., Avsian-Kretchmer, O., Hsueh A. J.W.: EP1861416A1 (2007).
71. Zhang, J., Avsian-Kretchmer, O., Hsueh, A. J. W.: US20060229250A1 (2006).
72. Amengual, R., Marsol, C., Mayeux, E., Sierra, M., Wagner, P.: WO2006133926A1(2006).
73. Burstein, S. H., Chen, D. J., Zurier, R.B.: US20040186166A1 (2004).
74. Amatruda, J. M., Daruwala, P., Erondu, N. E., Macneil, D.J.,Moller, D. E., Qian, S.: US20080064632A1(2008).
75. Zbucki RL, Sawicki B, Hryniewicz A, Winnicka MM. Cannabinoids enhance gastric X/A-like cells activity. Folia Histochem Cytobiol 2008; 46(2): 219-224.
76. Cani PD, Montoya ML, Neyrinck AM, Delzenne NM, Lambert DM. Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. Br J Nutr 2004; 92(5): 757-761.